Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153173 · ClinicalTrials.gov registry record · Phase 2
Mirdametinib in Histiocytic Disorders
A Phase 2 study of Histiocytic Disorders and Langerhans Cell Histiocytosis (LCH), sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06153173 is a Phase 2 study of Histiocytic Disorders and Langerhans Cell Histiocytosis (LCH) that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06153173, a Phase 2 study of Histiocytic Disorders and Langerhans Cell Histiocytosis (LCH), is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
Conditions Studied
Interventions
- DRUG Mirdametinib
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2031-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06153173
The ClinicalTrials.gov registry entry for NCT06153173 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Histiocytic Disorders appearing as the primary indexed condition, and to 1 intervention - of which Mirdametinib is the first listed.
NCT06153173 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06153173 about?
NCT06153173 is a clinical study titled "Mirdametinib in Histiocytic Disorders". The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
What is the current status of trial NCT06153173?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-02-05. Estimated completion is 2031-03.
What conditions does trial NCT06153173 study?
This clinical trial studies the following conditions: Histiocytic Disorders, Langerhans Cell Histiocytosis (LCH), Rosai-Dorfman Disease (RDD), Juvenile Xanthogranuloma (JXG).
What interventions are being tested in trial NCT06153173?
The interventions under investigation include: Mirdametinib (DRUG).
Who is sponsoring clinical trial NCT06153173?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153173 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Histiocytic Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.